glp-1 gip therapy alternatives 2025 What is the pipeline for future medications for obesity? The GLP-1 Revolution Continues

Its a structured dose escalation ranging from 2.5 mg to 15 mg

Its precise mechanism makes it a valuable candidate for research in muscle growth enhancement, anti-aging therapies, and recovery processes, offering focused benefits without the broader hormonal side effects often associated with growth hormone secretagogues

Heres the month-by-month breakdown based on aggregate data from 338 Phase 2 trial participants: This timeline is remarkably consistent across patients

Vehicle controls in matched buffer, GHRP-6 or GHRP-2 as non-selective GHS reference compounds at equivalent molar concentrations, GHS-R1a antagonist [D-Lys3]-GHRP-6 confirming receptor specificity, and concurrent prolactin and cortisol measurement endpoints confirming selectivity in the specific model and species used

[DOI] [PMC free article] [PubMed] [Google Scholar] 50.DAmico R., Cordaro M., Siracusa R., Impellizzeri D., Trovato Salinaro A., Scuto M., Ontario M.L., Crea R., Cuzzocrea S., Di Paola R., et al